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Background: MicroRNAs have been implicated in cancer but studies on their role in precancer, such as leukoplakia,
are limited. Sequence variations at eight miRNA and four miRNA processing genes were studied in 452 healthy
controls and 299 leukoplakia patients to estimate risk of disease.
Results: Genotyping by TaqMan assay followed by statistical analyses showed that variant genotypes at Gemin3
and mir-34b reduced risk of disease [OR = 0.5(0.3–0.9) and OR = 0.7(0.5–0.9) respectively] in overall patients as well as
in smokers [OR = 0.58(0.3–1) and OR = 0.68(0.5–0.9) respectively]. Among chewers, only mir29a significantly
increased risk of disease [OR = 1.8(1–3)]. Gene-environment interactions using MDR-pt program revealed that mir29a,
mir34b, mir423 and Xpo5 modulated risk of disease (p < 0.002) which may be related to change in expression of
these genes as observed by Real-Time PCR assays. But association between polymorphisms and gene expressions
was not found in our sample set as well as in larger datasets from open access platforms like Genevar and 1000
Genome database.
Conclusion: Variations in microRNAs and their processing genes modulated risk of precancer but further in-depth
study is needed to understand mechanism of disease process.
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Leukoplakia is one of the major forms of oral precancer-
ous lesions that can be clinically characterized primarily
as a non-scratchable white lesion of the oral mucosa [1].
Incidence of this lesion varies from 1.3 to 2.1 per 1000
individuals in different parts of India depending on the
types of tobacco habits but prevalence of this lesion was
found to be about 17 per 1000 tobacco users [2]. Several
factors like tobacco carcinogen, alcohol, HPV infection
and genetic predisposition are suspected causative
agents for leukoplakia [3]. A survey on Indian popula-
tions found that ~80% of oral cancers were preceded by
pre-cancerous lesions and oral leukoplakia being most
common among them [4].* Correspondence: broy@isical.ac.in
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unless otherwise stated.MicroRNAs (miRNAs) are highly conserved small
regulatory RNAs that play fundamental biological roles
in all known plant and animal species [5]. They are tran-
scribed mainly by RNA Pol II and go through series of
processing before they become functionally active. Initial
large primary transcripts or “pri-miRNAs” are sequen-
tially cleaved in the nucleus by microprocessor complex
which contains DROSHA ribonuclease and DGCR8, to
form premature precursors or pre-miRNA. These 70–
80 nt long precursors are exported to cytoplasm by
RAN-GTPase and Exportin 5 (XPO5), after which they
are further cleaved to produce ‘mature’ (~22 nucleotides
in length) single-stranded miRNAs that are bound to the
RISC complex comprising DICER, GEMIN3, AGO1 etc.
MiRNAs are reported to function by binding ‘target’
mRNAs through partial or complete base-pair comple-
mentarity at 3′UTR and this leads to either a decreased
rate of polypeptide synthesis or complete degradation of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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2500 miRNA molecules have been identified in the hu-
man genome and they play important roles in a broad
range of physiological and pathological processes [8-10].
Genetic variation at miRNA and their processing genes
have potential to affect regulation of multiple cellular
pathways instrumental in cancer development and sus-
ceptibility [11]. In order to investigate their potential
role in altering risk of oral leukoplakia, single nucleotide
polymorphisms (SNPs) in four miRNA processing and
pri-miR and pre-miR regions of eight miRNA genes were
studied in leukoplakia patients. Then, gene-environment
interaction was studied using Multi Dimensionality Re-
duction (MDR) approach to understand risk of leukopla-
kia. We also examined whether expression of these genes
are modulated by SNPs not only in our samples but also




This study was approved by “Review committee for pro-
tection of research risk to humans, Indian Statistical In-
stitute”. Unrelated controls (n = 452) and oral leukoplakia
patients (n = 299) were recruited from two tertiary referral
hospitals, namely R. Ahmed Dental College and Hospital
[12] and Gurunanak Institute of Dental Science and
Research, Kolkata, India [13]. All patients and controls
had at least one kind of tobacco habit. Patients were re-
ferred to these hospitals for biopsy and diagnosis by pri-
mary health centers and were not under any prior
medication for leukoplakia. Unrelated controls visited
these hospitals for treatment of dental ailments, not re-
lated to any kind of precancer and cancer, and had no
family history of cancer. Demographic details and tobacco
habits were noted after written consent.
Sample collection and processing
Venous blood (~3 ml) was collected from all patients
and controls and stored at −20 ºC until DNA isolation.
Genomic DNA was isolated by salt extraction method
[14] and QIAamp DNA extraction kit (QIAGEN, Valencia,
CA). Biopsy tissues collected from patients were used for
histopathology and expression study. Normal tissues were
also collected from few individuals who were recruited as
controls. To study RNA expression, part of the biopsy tis-
sues were collected in RNA Later and stored at −20°C
until use. Total RNA was extracted using All Prep DNA/
RNA Mini Kit (QIAGEN, Valencia, CA) following proto-
col provided with the kit.
SNP selection
All 12 SNPs selected in this study have been implicated
in various tobacco related squamous cell carcinomas inprevious reports [15-18]. Eight of them: rs11614913(C/T)
at miR-196a2, rs2910164 (G/C) at miR-146a, rs7372209
(C/T) at miR-26a-1, rs6505162 (A/C) at miR-423,
rs213210 (A/G) at miR-219-1, rs2660304 (G/T) at miR-
137, rs2187473 (T/C) at miR-34b and rs24168 (A/G) at
miR-29a are located at miRNAs. Remaining four SNPs
are located in miRNA processing genes: rs197412(C/T)
at GEMIN3, rs3742330 (A/G) at DICER1, rs11077 (A/C)
at XPO5 and rs14035(C/T) at RAN [15,16].
Genotyping
Genotyping at all SNPs was performed by Taqman
method in 7900HT FAST Real-Time PCR system (Applied
Biosystems, USA). To reconfirm genotypes determined
by Taqman method, ~15% of the samples were ran-
domly selected and further genotyped by a different per-
son (who had no prior information of the genotypes)
either by re-sequencing (ABI 3100 Genetic Analyzer,
Applied Biosystem, USA) or PCR-RFLP. Except for
mir146a and mir196a-2 [19], primers for sequencing
and RFLP studies were designed by us.
Gene expression
Expressions of miR processing genes (Gemin3 and Xpo5)
and miRNAs (mir29a, mir34b and mir423) in 19 leukopla-
kia and 19 control tissues were studied by TaqMan
method (7900HT Fast Real Time PCR System, Applied
Biosystem, USA). Normalized expression of a gene was
calculated as ΔCt with respect to endogenous control
genes, RNase P or RNU44 in case of miR processing or
miRNA genes respectively.
Statistical analysis
Each SNP data from controls was checked for Hardy-
Weinberg equilibrium (HWE). Male/female distribution
and number of smoker/chewers were different in control
and leukoplakia groups. So, age-, sex- and tobacco dose-
adjusted risk of leukoplakia was calculated as odds ratios
(ORs) with 95% confidence intervals (CIs) for all geno-
types by binary logistic regression analysis using PLINK
software [20]. Risk of leukoplakia was also calculated in
patients stratifying them on basis of their tobacco habits.
Chi-square test with Yates’ correction, when necessary,
was used for comparison of genotype proportions. Three
different genetic models for disease, such as, dominant
model (comparing homozygous major genotype with
variant allele-carrying genotypes), recessive model (com-
paring major allele-carrying genotypes with homozygous
variant genotype) and additive model (i.e. trend test)
were considered in analysis. Since there were multiple
SNPs involved in the study, multiple testing correct-
ions were done using Benjamini-Hochberg method [21].
Spearman’s correlation test was performed to evaluate
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notypes at SNPs.
Multi dimensionality reduction (MDR) analysis
To analyze possible interaction among SNPs and other
covariates, non-parametric MDR approach was used
[22,23]. All 12 SNPs and covariates (Pack Year and
Chewing Year) were considered to construct interaction
models in patients comparing with those of control indi-
viduals. For every SNP, three genotypes were coded as 0,
1 and 2; no-smoking/chewing dose was coded as 0, low
smoking/chewing dose (<mean PY or CY in controls)
coded as 1 and high smoking/chewing dose (>mean PY
or CY in controls) was coded as 2. Statistical significance
was determined using permutation testing in MDRpt
(version 1.0_beta_2). Ten fold cross-validation and 1000
fold permutation testing were used and interaction
models with p-value <0.05 were considered as significant.
Cross-validation consistency (CVC) score is a measure of
degree of consistency with which identified interaction is
most evident among all possibilities [24]. Among signifi-
cant models, cross validation consistency (CVC) ≥ 9 was
considered as important, as the data was cross validated
10 times by MDR. Best model was then defined with lar-
gest testing balance accuracy (TBA) among important
models. Testing Balanced Accuracy (TBA) is a measure of
degree to which interaction accurately predicts case–
control status, taking into account the ratio of cases to
controls, with scores between 0.50 (indicating that
model predicts no better than chance) and 1.00 (indicat-
ing perfect prediction). Scores of at least 0.55 are con-
sidered ‘interesting’ [24].
Analysis of 1000 Genome database
Small RNA expression data and whole genome sequen-
cing data on 485 individuals of 1000 Genome project
has been recently released and is openly accessible [25].
MiRNA RNA-Seq and genotype data, obtained from
lymphoblastoid cell line, of 87 Caucasian was extracted
for our analysis. MiRNA RNA-Seq data was analyzed
using miRExpress software [26] which converts available
FASTQ data into read counts. Read counts were nor-
malised using two methods- i) RPM or Reads per million
[27] and ii) DEseq tool from Bioconductor software [28].
Genotype data were obtained from 1000 Genome web
browser.
Analysis of data from Genevar platform
Genevar (GENe Expression Variation) platform has gene
variation and gene expression data from HapMap3
population (http://www.sanger.ac.uk/resources/software/
genevar/) [29]. After launching the application in a Java
enabled computer, gene name and rs ID is entered in the
“eQTL-SNP-Gene” option. Genevar provides spearman’scorrelation coefficient and p value for analysis between
gene expression and genotypes for 8 different populations.
Results
Controls as well as patients were recruited from same
dental hospitals and were ethnically similar. Although
both smokers and chewers are equally affected by leuko-
plakia, but abundance of smokers (85%, including exclu-
sive smokers and mixed habitués) in the leukoplakia
group is corroborated by the high number of males (88%)
in leukoplakia patients (Table 1). Analysis of genotypes in
control samples showed that population was in HWE
(p =0.08 to 1.0 for all SNPs). There was 100% concordance
between genotypes determined by different methods.
Histopathologically, 73% of leukoplakia tissues had mild
dysplasia while remaining 27% had moderate dysplasia.
Minor allele homozygote at Gemin3 reduced risk of
leukoplakia at both allelic and genotypic level (p = 0.04
and 0.03 respectively) (Table 2). Genotypes containing
minor allele at mir-34b also reduced risk of leukoplakia
(p = 0.05). When stratified on basis of tobacco habits,
Gemin3 and mir-34b reduced risk of leukoplakia among
smokers too [p = 0.05 and 0.04 respectively] while minor
allele homozygous genotype at mir-29a increased risk of
leukoplakia significantly [p = 0.05] among chewers. But
none of the associations remained significant after multiple
testing corrections. Combined effect of risk genotypes at
Gemin3 and mir34b, was also estimated on the basis of
their weighted O.R. [13]. It was found that combination of
TT at Gemin3 and CT or TT at mir34b together reduced
risk of leukoplakia [OR = 0.7 (0.5–0.9), p = 0.02].
Fourteen factors [12 SNPs along with tobacco smoking
(PY) and/or chewing dose (CY)] were considered in
MDR analysis but maximally six factors were taken for
interaction. Three-, four-, five- and six-factors gene-
environment interaction models were identified and
model/s with an average cross-validation consistency
(CVC) of 9 out of 10 and p value of <0.05 in MDR per-
mutation testing program (MDR-pt) were considered to
be significant (Table 3). Three significant models were
observed: one model comprised PY, CY and mir196a2
with Testing Balance Accuracy or case–control status
prediction accuracy of 67% (p < 0.001), second model
consisted of PY, CY, mir34b and mir29a with prediction
accuracy of 67% (p < 0.001) and lastly PY, CY, mir29a,
mir34b, mir423 and Xpo5 with prediction accuracy of
62% (p < 0.002). So, gene-environment interaction seems
to modulate risk of leukoplakia.
In order to compare expression of Gemin3, Xpo5,
mir34b, mir29a, mir423 on the basis of genotypes, we cal-
culated ΔCt value in leukoplakia tissues with respect to
endogenous gene (Ctgene of interest – Ct RNASEP or RNU44).
On performing Spearman’s correlation test between ΔCt
values and genotypes of a gene, no significant association
Table 1 Demography and tobacco habits of leukoplakia patients and controls
Subjects and tobacco habits Control [N = 452] (%) Leukoplakia [N = 299] (%) p-value
Male 367(81) 263(88) 0.01
Female 85(19) 36(12)
Age (Mean ± SD) 48.5 ± 11 47.4 ± 10.4 0.18
Exclusive smokersa 175(39) 170(57) <0.001
Exclusive chewersb 185(42) 44(15) <0.001
Mixed habituésc 92(19) 85(28) 0.01
aExclusive smokers have tobacco smoking habit only.
bExclusive chewers have tobacco chewing/dipping habit only.
cMixed habitués have both tobacco smoking and chewing habits.
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Again, after analyzing freely available miR-RNASeq data
generated by 1000 Genome, no significant association
was observed between expression and genotypes at
SNPs of significant miRNAs by performing correlation
test (p = 0.2–0.9 in DEseq normalized data, p = 0.3–0.8
in RPM normalized data). For Gemin3 and Xpo5, we
also checked available eQTL-SNP-Gene analysis be-
tween genotypes at SNP and gene expression for CEU
population in Genevar platform which contains geno-
type and expression data of HapMap 3 population. But,
we did not get any significant difference in expression
across genotypes (p value = 0.11 and 0.16 respectively).
But interestingly, when we compared expression ofTable 2 Polymorphisms at miRNA and miRNA processing gen
p-values are shown)
Gene (SNP)c Genotype and Alleles Control









(bTobacco Smokers : Contro
Gemin3(rs197412) TT + CT 222(86)/
CC 35(14)/2
mir34b(rs2187473) CC 80(32)/9
CT + TT 169(68)/
(bTobacco Chewers : Contro
mir29a(rs24168) GG + AG 228(84)/
AA 44(16)/2
aadjusted for age, sex and tobacco habits.
bSmokers/chewers include exclusive smokers/chewers along with mixed habitués.
cGemin3- Dominant model; mir34b and mir29a-Recessive model (with respect to risk
Few individuals could not be genotyped at certain loci.these miRNA and processing genes between leukoplakia
and “control” tissues, we found significant difference in
expression (Figure 1).
Discussion and conclusion
Variant homozygote at Gemin3 reduced risk of leukopla-
kia significantly (OR = 0.5, 95% CI = 0.3–0.9). Few other
studies had also reported association between oral pre-
malignant lesion and SNP at Gemin3 [15,30,31]. This
polymorphism did not seem to alter Gemin3 expression
in our small dataset of 19 leukoplakia tissues or larger
Hapmap3 data set. This SNP lies in the exonic region
and, thus, may alter gene activity or could be in the
vicinity of other causal SNPs. Study by Clague et al. [15]es and risk of leukoplakia (Only SNPs with significant



















Table 3 MDR interaction analysis between loci and tobacco habits in “leukoplakia vs control” group
Best predictive interactive modela TBAb CVCc 1000 permutation p valued
PY CY mir196a2 0.67 9 <0.001
PY CY mir34b mir29a 0.67 10 <0.001
PY CY mir29a mir34b mir423 Xpo5 0.62 9 <0.002
aBest model was selected as one with minimum prediction error, maximum CVC and significant p-value after 1000 permutation.
bTBA corresponds to testing balanced accuracy, the accuracy with which the model can predict disease status.
cCross Validation Consistency: calculated out of 10.
dp value calculated after running 1000 permutations in MDR-pt program.
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mir26a-1 and rs3742330 at Dicer1 altered risk of oral
pre-malignant lesion but except Gemin3, our study
could not find association between polymorphisms at
mir26a-1 and Dicer1 and risk of leukoplakia (data not
shown). It is worth mentioning that sample size was
smaller (136 patients and 136 controls) in the report by
Clague et al. [15]. Variant allele containing genotypes at
mir34b were found to reduce risk of leukoplakia in over-
all sample population (p = 0.05) as well as in smokers
(p = 0.04) (Table 2). Again, we did not find any difference
in expression of mir34b across its three genotypes at
rs2187473. But this SNP lies 1 kb downstream of
rs4938723 that has been shown to lie in the promoter
region of mir34b and influence risk of various types of
cancer [32-34]. So, it needs to be investigated whether
these two SNPs are in LD. In our recent study on cancer
patients, we got similar results for Gemin3 and mir-34bFigure 1 Comparison of gene expression of three microRNAs and two
to control tissues from different individuals.[13]. It is interesting to study how these two polymor-
phisms alter risk of both oral precancer and cancer. It
was found that risk of leukoplakia was reduced signifi-
cantly (p =0.02) when patients harbored protective vari-
ant genotypes at both loci (CC at Gemin3 and CT/TT at
mir34b).
In order to analyze implication of polymorphism on gene
expression, we not only studied our sample set (N = 19)
but also explored publicly available databases like 1000
Genome and Genevar platform. We assumed that if a SNP
alters gene expression, it would do so in all cells including
lymphoblastoid cell line. Although, the sample size was in
the range of 87–100 in databases, we still did not find any
significant variation in expression across genotypes at a
SNP, similar to results in our sample set (data not shown).
Alongside we used MDR to predict statistical epistasis
which describes an effect exceeding the combined effects
of each genetic factor [35]. It has been observed that theremicroRNA processing genes in leukoplakia tissues with respect
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and mir29a, mir34b, mir423 and Xpo5 and, as a result,
risk of leukoplakia may be modulated (Table 3). So, we
compared expression of these genes in leukoplakia with
respect to control tissues to understand whether there is
any deregulation in expression independent of polymorph-
ism. Although expression of mir29a, mir34b, mir423 and
Xpo5 was not modulated by genotypes at SNPs but ex-
pression of these genes was significantly different in leuko-
plakia with respect to control tissues. This finding further
emphasizes importance of these miRNAs in leukoplakia
development. In a recent report, miR-29a was found to be
down regulated in serum of patients with high risk oral le-
sions (HRL), showing high specificity in identifying HRLs
[36]. They also observed that miR-423 was differentially
expressed across oral squamous cell carcinoma, carcinoma
in situ, and controls. MiR-423 was found to significantly
promote cell growth and cell cycle progression at the
G1/S transition in HCC cells [37]. Functional studies have
reported both up- and down- regulation of miR-34b in
tongue and oral squamous cell carcinoma, respectively
[17,38]. MiR-34b is also involved in a number of
tumorigenesis-related molecular mechanisms, including
epithelial-mesenchymal-transition (EMT) [39]. So, it sug-
gests that our observation related to mir29a, mir34b,
mir423 and Xpo5 in leukoplakia might have important im-
plications in transformation of normal epithelium to
leukoplakia.
There are several reports on association of microRNA
SNPs with a wide repertoire of disease [11,40] but most
of them did not show how these variations actually alter
miRNA expression or activity. Here, it is shown that
SNPs at miRNA and processing genes are associated
with risk of leukoplakia statistically but most of the asso-
ciations are lost after correction for multiple testing.
First limitation of the study is small number of candidate
SNPs so it is important to re-examine association study
with more number of SNPs since it is known that a large
number of miRNAs are associated with risk of different
precancer and cancer. Second limitation is sample size
of leukoplakia patients. Partially, this might be due to
the fact that many precancer patients prefer to avoid
hospital since precancer is not life-threatening. But it is
always worthwhile to study larger number of patients.
Importance of this study lies in the observation that ex-
pression of genes, which interact with environmental
factors to modulate risk of leukoplakia, was significantly
altered in leukoplakia compared to control tissues
(Figure 1). Since miRNAs target genes involved in cell
proliferation, apoptosis etc., it is essential not only to
study expression of more miRNAs involved in these
pathways but also explore significance of more miRNA-
associated polymorphisms on large sample sets to valid-
ate their significance in leukoplakia.Competing interests
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